Tedalinab, also known GRC-10693, isa potent and selective cannabinoid CB2 receptor agonist under development for the treatment of osteoarthritis and neuropathic pain. It has a very high selectivity of 4700x for CB2 over the related CB1 receptor, has good orally bioavailable bioavailability and has shown promising safety results and effective analgesic and antiinflammatory actions in early clinical trials. References:

纯度：≥98%

CAS：916591-01-0